Re: Fwd: FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placebo

[Guest guest]

Hi Val, I took Paxil for a short time, years ago (and before I'd begun hearing all the horrible things about it). At first it seemed fine, but within weeks (a couple months) it was not "fine" and all symptoms it was supposed to help with only intensified. I went on to Zoloft from there. I like Zoloft! LOL I haven't used it myself in a long time, but my sons both have. They each did great with it (for them, it was used to address OCD). My younger son did use Effexor for a bit. He had no side effects at all, but it didn't help his symptoms either. lol It seems I do remember hearing that adults seem to have a harder time with Effexor for some reason. There are a number of meds out there which may help you when you're able to fill your rx and I hope you find just the right one! Hugs, Challis Valene wrote: Thanks n- I will ask my doctor about this. I have already gotten to the point that I don't care if I live or die most of the time. But, never have I thought about taking my own life. And if there is any chance that this medicine may make me become suicidal, I don't want to be on it. I know some people who are taking effexor for

their depression. But, from the symptoms they have gone through with that medicine, I know I don't want to be on it. Yes, Monday, I am going to call my doctor and talk to her about this medication. And I'm also going to do a little Internet research as well. God bless... http://mscopgirl.blogspot.com http://360.yahoo.com/vallee45 -- Re: Fwd: FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placebo Valene, I have a cousin who was prescribed this junk, and became very suicidal. He told his doctor and they switched him to something MUCH milder, and he took it for a few months, and has been off it for years. Question your doctor, as this stuff, as Sharon pointed out in her citation, has a bad reputation. Love to you, Valene! n FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placeboTo: MEDWATCH@...MedWatch - The FDA Safety Information and Adverse Event Reporting ProgramGlaxoKline (GSK) and FDA notified healthcare professionals ofchanges to the Clinical Worsening and Suicide Risk subsection of theWARNINGS section in the prescribing Information for Paxil and Paxil CR.These labeling changes relate to adult patients, particularly those whoare younger adults. A recent

meta-analysis conducted of suicidal behavior and ideation inplacebo-controlled clinical trials of paroxetine in adult patients withpsychiatric disorders including Major Depressive Disorder (MDD), otherdepression and non-depression disorders. Results of this analysis showeda higher frequency of suicidal behavior in young adults treated withparoxetine compared with placebo. Further, in the analysis of adultswith MDD (all ages), the frequency of suicidal behavior was higher inpatients treated with paroxetine compared with placebo. This differencewas statistically significant; however, as the absolute number andincidence of events are small, these data should be interpreted withcaution. All of the reported events of suicidal behavior in the adultpatients with MDD were non-fatal suicide attempts, and the majority ofthese attempts (8 of 11) were in younger adults aged 18-30. These MDDdata suggest that the higher frequency

observed in the younger adultpopulation across psychiatric disorders may extend beyond the age of 24.It is important that all patients, especially young adults and those whoare improving, receive careful monitoring during paroxetine therapyregardless of the condition being treated. Read the complete MedWatch 2006 Safety Summary, including links to theDear Healthcare Professional Letter and the revised approved productlabeling at: http://www.fda.gov/medwatch/safety/2006/safety06.htm#paxil_________________________________________________________________Thank you for using FDA MedWatch as a trusted source for timely safety information on drugs, devices and diagnostics regulated by the U.S. Food and Drug Administration. If you find this e-mail notification helpful, please consider telling colleagues and friends about MedWatch and this e-mail notification process. They can learn more and subscribe to the e-list

at http://www.fda.gov/medwatch.To send a comment or question to the MedWatch program: http://www.fda.gov/medwatch/feedback.htm

[Guest guest]

http://www.rxlist.com/cgi/generic3/rebif.htm --- Well, you DID ask!!!

Love, n

FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placeboTo: MEDWATCH@...MedWatch - The FDA Safety Information and Adverse Event Reporting ProgramGlaxoKline (GSK) and FDA notified healthcare professionals ofchanges to the Clinical Worsening and Suicide Risk subsection of theWARNINGS section in the prescribing Information for Paxil and Paxil CR.These labeling changes relate to adult patients, particularly those whoare younger adults. A recent meta-analysis conducted of suicidal behavior and ideation inplacebo-controlled clinical trials of paroxetine in adult patients withpsychiatric disorders including Major Depressive Disorder (MDD), otherdepression and non-depression disorders. Results of this analysis showeda higher frequency of suicidal behavior in young adults treated withparoxetine compared with placebo. Further, in the analysis of adultswith MDD (all ages), the frequency of suicidal behavior was higher inpatients treated with paroxetine compared with placebo. This differencewas statistically significant; however, as the absolute number andincidence of events are small, these data should be interpreted withcaution. All of the reported events of suicidal behavior in the adultpatients with MDD were non-fatal suicide attempts, and the majority ofthese attempts (8 of 11) were in younger adults aged 18-30. These MDDdata suggest that the higher frequency observed in the younger adultpopulation across psychiatric disorders may extend beyond the age of 24.It is important that all patients, especially young adults and those whoare improving, receive careful monitoring during paroxetine therapyregardless of the condition being treated. Read the complete MedWatch 2006 Safety Summary, including links to theDear Healthcare Professional Letter and the revised approved productlabeling at: http://www.fda.gov/medwatch/safety/2006/safety06.htm#paxil_________________________________________________________________Thank you for using FDA MedWatch as a trusted source for timely safety information on drugs, devices and diagnostics regulated by the U.S. Food and Drug Administration. If you find this e-mail notification helpful, please consider telling colleagues and friends about MedWatch and this e-mail notification process. They can learn more and subscribe to the e-list at http://www.fda.gov/medwatch.To send a comment or question to the MedWatch program: http://www.fda.gov/medwatch/feedback.htm

[Guest guest]

I sure did! Thanks, n. ) "It is produced by recombinant DNA technology using genetically engineered Chinese Hamster Ovary cells into which the human interferon beta gene has been introduced." Challis n Rojas wrote: http://www.rxlist.com/cgi/generic3/rebif.htm

--- Well, you DID ask!!! Love, n FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placeboTo: MEDWATCH@...MedWatch - The FDA Safety Information and Adverse Event Reporting ProgramGlaxoKline (GSK) and FDA notified healthcare professionals ofchanges to the Clinical Worsening and Suicide Risk subsection of theWARNINGS section in the prescribing Information for Paxil and Paxil CR.These labeling changes relate to adult patients, particularly those whoare younger adults. A

recent meta-analysis conducted of suicidal behavior and ideation inplacebo-controlled clinical trials of paroxetine in adult patients withpsychiatric disorders including Major Depressive Disorder (MDD), otherdepression and non-depression disorders. Results of this analysis showeda higher frequency of suicidal behavior in young adults treated withparoxetine compared with placebo. Further, in the analysis of adultswith MDD (all ages), the frequency of suicidal behavior was higher inpatients treated with paroxetine compared with placebo. This differencewas statistically significant; however, as the absolute number andincidence of events are small, these data should be interpreted withcaution. All of the reported events of suicidal behavior in the adultpatients with MDD were non-fatal suicide attempts, and the majority ofthese attempts (8 of 11) were in younger adults aged 18-30. These MDDdata suggest that the higher

frequency observed in the younger adultpopulation across psychiatric disorders may extend beyond the age of 24.It is important that all patients, especially young adults and those whoare improving, receive careful monitoring during paroxetine therapyregardless of the condition being treated. Read the complete MedWatch 2006 Safety Summary, including links to theDear Healthcare Professional Letter and the revised approved productlabeling at: http://www.fda.gov/medwatch/safety/2006/safety06.htm#paxil_________________________________________________________________Thank you for using FDA MedWatch as a trusted source for timely safety information on drugs, devices and diagnostics regulated by the U.S. Food and Drug Administration. If you find this e-mail notification helpful, please consider telling colleagues and friends about MedWatch and this e-mail notification process. They can learn more and subscribe to

the e-list at http://www.fda.gov/medwatch.To send a comment or question to the MedWatch program: http://www.fda.gov/medwatch/feedback.htm

[Guest guest]

I have been trying to get off this stuff for a while now. It has been a little over a week and I still feel lousy. I have sweats, chills, vomiting, crying, laughing, and that's just the bad stuff. I started taking paxil last july, so it hasn't even been a year. I wish I had done a little investigating before I had started it. I would tell any person who will listen; do not take this drug. There are so many other one's out there. I guess I was venting a little...sorry. This really has been a difficult ordeal for me. Dawn KSmyelin groovy wrote: Hi Val, I took Paxil for a short time, years ago (and before I'd begun hearing all the horrible things about it). At first it seemed fine, but within

weeks (a couple months) it was not "fine" and all symptoms it was supposed to help with only intensified. I went on to Zoloft from there. I like Zoloft! LOL I haven't used it myself in a long time, but my sons both have. They each did great with it (for them, it was used to address OCD). My younger son did use Effexor for a bit. He had no side effects at all, but it didn't help his symptoms either. lol It seems I do remember hearing that adults seem to have a harder time with Effexor for some reason. There are a number of meds out there which may help you when you're able to fill your rx and I hope you find just the right one! Hugs, Challis Valene wrote: Thanks n- I will ask my doctor about this. I have already gotten to the point that I don't care if I live or die most of the time. But, never have I thought about taking my own life. And if there is any chance that this medicine may make me become suicidal, I don't want to be on it. I know some people who are taking effexor for their depression. But, from the symptoms they have gone through with that medicine, I know I don't want to be on it. Yes, Monday, I am going to call my doctor and talk to

her about this medication. And I'm also going to do a little Internet research as well. God bless... http://mscopgirl.blogspot.com http://360.yahoo.com/vallee45 -- Re: Fwd: FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placebo Valene, I have a cousin who was prescribed this junk, and became very suicidal. He told his doctor and they switched him to something MUCH milder, and he took it for a few months, and has been off it for years. Question your doctor, as this stuff, as Sharon pointed out in her

citation, has a bad reputation. Love to you, Valene! n FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placeboTo: MEDWATCH@...MedWatch - The FDA Safety Information and Adverse Event Reporting ProgramGlaxoKline (GSK) and FDA notified healthcare professionals ofchanges to the Clinical Worsening and Suicide Risk subsection of theWARNINGS section in the prescribing Information for Paxil and Paxil CR.These labeling changes relate to adult patients, particularly those whoare younger adults. A recent meta-analysis conducted of suicidal behavior and ideation inplacebo-controlled clinical trials of paroxetine in adult patients withpsychiatric disorders

including Major Depressive Disorder (MDD), otherdepression and non-depression disorders. Results of this analysis showeda higher frequency of suicidal behavior in young adults treated withparoxetine compared with placebo. Further, in the analysis of adultswith MDD (all ages), the frequency of suicidal behavior was higher inpatients treated with paroxetine compared with placebo. This differencewas statistically significant; however, as the absolute number andincidence of events are small, these data should be interpreted withcaution. All of the reported events of suicidal behavior in the adultpatients with MDD were non-fatal suicide attempts, and the majority ofthese attempts (8 of 11) were in younger adults aged 18-30. These MDDdata suggest that the higher frequency observed in the younger adultpopulation across psychiatric disorders may extend beyond the age of 24.It is important that all patients, especially

young adults and those whoare improving, receive careful monitoring during paroxetine therapyregardless of the condition being treated. Read the complete MedWatch 2006 Safety Summary, including links to theDear Healthcare Professional Letter and the revised approved productlabeling at: http://www.fda.gov/medwatch/safety/2006/safety06.htm#paxil_________________________________________________________________Thank you for using FDA MedWatch as a trusted source for timely safety information on drugs, devices and diagnostics regulated by the U.S. Food and Drug Administration. If you find this e-mail notification helpful, please consider telling colleagues and friends about MedWatch and this e-mail notification process. They can learn more and subscribe to the e-list at http://www.fda.gov/medwatch.To send a comment or question to the MedWatch program: http://www.fda.gov/medwatch/feedback.htm

[Guest guest]

{{{{{{{{Dawn}}}}}}}} Challis Dawn Kammerer wrote: I have been trying to get off this stuff for a while now. It has been a little over a week and I still feel lousy. I have sweats, chills, vomiting, crying, laughing, and that's just the bad stuff. I started taking paxil last july, so it hasn't even been a year. I wish I had done a little investigating before I had started it. I would tell any person who will listen; do not take this drug. There are so many other one's out there. I guess I was venting a little...sorry. This really has been a difficult ordeal for me. Dawn KSmyelin groovy wrote: Hi Val, I took Paxil for a short time, years ago (and before I'd begun hearing all the horrible things about it). At first it seemed fine, but within weeks (a couple months) it was not "fine" and all symptoms it was supposed to help with only intensified. I went on to Zoloft from there. I like Zoloft! LOL I haven't used it myself in a long time, but my sons both have. They each did great with it (for them, it was used to address OCD). My younger son did use Effexor for a bit. He had no side effects at all, but it didn't help his symptoms either. lol It seems I do remember hearing that adults seem to have a harder time with Effexor for some reason. There are a number of meds out there which may help you when you're able to fill your rx and I hope

you find just the right one! Hugs, Challis Valene wrote: Thanks n- I will ask my doctor about this. I have already gotten to the point that I don't care if I live or die most of the time. But, never have I thought about taking my own life. And if there is any chance that this medicine may make me become suicidal, I

don't want to be on it. I know some people who are taking effexor for their depression. But, from the symptoms they have gone through with that medicine, I know I don't want to be on it. Yes, Monday, I am going to call my doctor and talk to her about this medication. And I'm also going to do a little Internet research as well. God bless... http://mscopgirl.blogspot.com http://360.yahoo.com/vallee45 -- Re: Fwd: FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placebo Valene, I have a cousin who was prescribed this junk, and became very suicidal. He told his doctor and they switched him to something MUCH milder, and he took it for a few months, and has been off it for years. Question your doctor, as this stuff, as Sharon pointed out in her citation, has a bad reputation. Love to you, Valene! n FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placeboTo: MEDWATCH@...MedWatch - The FDA Safety Information and Adverse Event Reporting ProgramGlaxoKline (GSK) and FDA notified healthcare professionals ofchanges to the Clinical Worsening and Suicide Risk subsection of theWARNINGS section in the prescribing Information for Paxil and Paxil CR.These labeling

changes relate to adult patients, particularly those whoare younger adults. A recent meta-analysis conducted of suicidal behavior and ideation inplacebo-controlled clinical trials of paroxetine in adult patients withpsychiatric disorders including Major Depressive Disorder (MDD), otherdepression and non-depression disorders. Results of this analysis showeda higher frequency of suicidal behavior in young adults treated withparoxetine compared with placebo. Further, in the analysis of adultswith MDD (all ages), the frequency of suicidal behavior was higher inpatients treated with paroxetine compared with placebo. This differencewas statistically significant; however, as the absolute number andincidence of events are small, these data should be interpreted withcaution. All of the reported events of suicidal behavior in the adultpatients with MDD were non-fatal suicide attempts, and the majority ofthese attempts (8 of

11) were in younger adults aged 18-30. These MDDdata suggest that the higher frequency observed in the younger adultpopulation across psychiatric disorders may extend beyond the age of 24.It is important that all patients, especially young adults and those whoare improving, receive careful monitoring during paroxetine therapyregardless of the condition being treated. Read the complete MedWatch 2006 Safety Summary, including links to theDear Healthcare Professional Letter and the revised approved productlabeling at: http://www.fda.gov/medwatch/safety/2006/safety06.htm#paxil_________________________________________________________________Thank you for using FDA MedWatch as a trusted source for timely safety information on drugs, devices and diagnostics regulated by the U.S. Food and Drug Administration. If you find this e-mail notification helpful, please consider telling colleagues and friends about

MedWatch and this e-mail notification process. They can learn more and subscribe to the e-list at http://www.fda.gov/medwatch.To send a comment or question to the MedWatch program: http://www.fda.gov/medwatch/feedback.htm

[Guest guest]

Hello Challis-

I was talking to my daughter yesterday. She was telling me that she's on Zoloft now. She was diagnosed with post-pardem depression and post traumatic shock. She says she does well on it. A couple of years back, I was diagnosed with agoraphobia. My doctor put me on Zoloft. It had no effect on me. She then switched my to Paxil. I wasn't on it long enough to be able to really know how I was doing on it. I took myself off after it became too expensive for me to handle. I still haven't gotten my prescription filled. My fiance said he would pay for me to get it, but he won't be getting paid until Friday. I think I can live with that. In the meantime, I am going to continue to research and see if I can find a less expensive way to go with this.

Thanks a bunch!! God bless...Val

-- Re: Fwd: FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placebo

Valene, I have a cousin who was prescribed this junk, and became very

suicidal. He told his doctor and they

switched him to something MUCH milder,

and he took it for a few months, and has been off it for years. Question your doctor, as this stuff, as Sharon

pointed out in her citation, has a bad

reputation. Love to you, Valene! n

FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placeboTo: MEDWATCH@...MedWatch - The FDA Safety Information and Adverse Event Reporting ProgramGlaxoKline (GSK) and FDA notified healthcare professionals ofchanges to the Clinical Worsening and Suicide Risk subsection of theWARNINGS section in the prescribing Information for Paxil and Paxil CR.These labeling changes relate to adult patients, particularly those whoare younger adults. A recent meta-analysis conducted of suicidal behavior and ideation inplacebo-controlled clinical trials of paroxetine in adult patients withpsychiatric disorders including Major Depressive Disorder (MDD), otherdepression and non-depression disorders. Results of this analysis showeda higher frequency of suicidal behavior in young adults treated withparoxetine compared with placebo. Further, in the analysis of adultswith MDD (all ages), the frequency of suicidal behavior was higher inpatients treated with paroxetine compared with placebo. This differencewas statistically significant; however, as the absolute number andincidence of events are small, these data should be interpreted withcaution. All of the reported events of suicidal behavior in the adultpatients with MDD were non-fatal suicide attempts, and the majority ofthese attempts (8 of 11) were in younger adults aged 18-30. These MDDdata suggest that the higher frequency observed in the younger adultpopulation across psychiatric disorders may extend beyond the age of 24.It is important that all patients, especially young adults and those whoare improving, receive careful monitoring during paroxetine therapyregardless of the condition being treated. Read the complete MedWatch 2006 Safety Summary, including links to theDear Healthcare Professional Letter and the revised approved productlabeling at: http://www.fda.gov/medwatch/safety/2006/safety06.htm#paxil_________________________________________________________________Thank you for using FDA MedWatch as a trusted source for timely safety information on drugs, devices and diagnostics regulated by the U.S. Food and Drug Administration. If you find this e-mail notification helpful, please consider telling colleagues and friends about MedWatch and this e-mail notification process. They can learn more and subscribe to the e-list at http://www.fda.gov/medwatch.To send a comment or question to the MedWatch program: http://www.fda.gov/medwatch/feedback.htm

[Guest guest]

Challis-

I read the information on the box that Rebif comes in. This is what it says: Each 0.5mL syringe contains 44mcg interferon beta- 1a, 27.3mg Manitol USP, 4mg Albumin Human USP, 0.4 mg sodium acetate and Sterile Water for injection USP. No preservative. Now....here's what really bothers me....Interferon beta- 1a is produced by Chinese hamster ovary cells. EEEEWWWW!!!

Before I found this out, I was having some weird smelling side effects. And I still do. Every day after taking my shot, I wake up and I can smell dead animals. Serious, not lying! Sometimes the odor will stay with me all day. Sometimes, just a few hours. But, nobody else seems to have this side effect. If I had read the box before taking my shots, I would probably have said, "Silly, it's all in your head, you just think you're smelling it because of what you read." But no, I read the box after using the meds for a couple of weeks.

Where did I get this from?....Can't seem to be able to make a comment without writing a novel. So sorry.

Many blessings...Val

-- FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placeboTo: MEDWATCH@...MedWatch - The FDA Safety Information and Adverse Event Reporting ProgramGlaxoKline (GSK) and FDA notified healthcare professionals ofchanges to the Clinical Worsening and Suicide Risk subsection of theWARNINGS section in the prescribing Information for Paxil and Paxil CR.These labeling changes relate to adult patients, particularly those whoare younger adults. A recent meta-analysis conducted of suicidal behavior and ideation inplacebo-controlled clinical trials of paroxetine in adult patients withpsychiatric disorders including Major Depressive Disorder (MDD), otherdepression and non-depression disorders. Results of this analysis showeda higher frequency of suicidal behavior in young adults treated withparoxetine compared with placebo. Further, in the analysis of adultswith MDD (all ages), the frequency of suicidal behavior was higher inpatients treated with paroxetine compared with placebo. This differencewas statistically significant; however, as the absolute number andincidence of events are small, these data should be interpreted withcaution. All of the reported events of suicidal behavior in the adultpatients with MDD were non-fatal suicide attempts, and the majority ofthese attempts (8 of 11) were in younger adults aged 18-30. These MDDdata suggest that the higher frequency observed in the younger adultpopulation across psychiatric disorders may extend beyond the age of 24.It is important that all patients, especially young adults and those whoare improving, receive careful monitoring during paroxetine therapyregardless of the condition being treated. Read the complete MedWatch 2006 Safety Summary, including links to theDear Healthcare Professional Letter and the revised approved productlabeling at: http://www.fda.gov/medwatch/safety/2006/safety06.htm#paxil_________________________________________________________________Thank you for using FDA MedWatch as a trusted source for timely safety information on drugs, devices and diagnostics regulated by the U.S. Food and Drug Administration. If you find this e-mail notification helpful, please consider telling colleagues and friends about MedWatch and this e-mail notification process. They can learn more and subscribe to the e-list at http://www.fda.gov/medwatch.To send a comment or question to the MedWatch program: http://www.fda.gov/medwatch/feedback.htm

[Guest guest]

I'm listening, Dawn-

I'm sorry you are having such a tough time on this stuff! Are you weaning yourself off of it, or are you trying the "cold turkey" approach? I have heard that with all anti-depressants, you should be weaned off of them because of the symptoms. I do hope you start feeling better soon. And really, I am listening. I'm doing my homework. I won't be taking the Paxil until I find out if it is the best for me.

Blessed be...Val

-- Re: Fwd: FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placebo

Valene, I have a cousin who was prescribed this junk, and became very

suicidal. He told his doctor and they

switched him to something MUCH milder,

and he took it for a few months, and has been off it for years. Question your doctor, as this stuff, as Sharon

pointed out in her citation, has a bad

reputation. Love to you, Valene! n

FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placeboTo: MEDWATCH@...MedWatch - The FDA Safety Information and Adverse Event Reporting ProgramGlaxoKline (GSK) and FDA notified healthcare professionals ofchanges to the Clinical Worsening and Suicide Risk subsection of theWARNINGS section in the prescribing Information for Paxil and Paxil CR.These labeling changes relate to adult patients, particularly those whoare younger adults. A recent meta-analysis conducted of suicidal behavior and ideation inplacebo-controlled clinical trials of paroxetine in adult patients withpsychiatric disorders including Major Depressive Disorder (MDD), otherdepression and non-depression disorders. Results of this analysis showeda higher frequency of suicidal behavior in young adults treated withparoxetine compared with placebo. Further, in the analysis of adultswith MDD (all ages), the frequency of suicidal behavior was higher inpatients treated with paroxetine compared with placebo. This differencewas statistically significant; however, as the absolute number andincidence of events are small, these data should be interpreted withcaution. All of the reported events of suicidal behavior in the adultpatients with MDD were non-fatal suicide attempts, and the majority ofthese attempts (8 of 11) were in younger adults aged 18-30. These MDDdata suggest that the higher frequency observed in the younger adultpopulation across psychiatric disorders may extend beyond the age of 24.It is important that all patients, especially young adults and those whoare improving, receive careful monitoring during paroxetine therapyregardless of the condition being treated. Read the complete MedWatch 2006 Safety Summary, including links to theDear Healthcare Professional Letter and the revised approved productlabeling at: http://www.fda.gov/medwatch/safety/2006/safety06.htm#paxil_________________________________________________________________Thank you for using FDA MedWatch as a trusted source for timely safety information on drugs, devices and diagnostics regulated by the U.S. Food and Drug Administration. If you find this e-mail notification helpful, please consider telling colleagues and friends about MedWatch and this e-mail notification process. They can learn more and subscribe to the e-list at http://www.fda.gov/medwatch.To send a comment or question to the MedWatch program: http://www.fda.gov/medwatch/feedback.htm

[Guest guest]

Dawn,

It took me 3 months to start feeling better after going off it. It is truly an evil drug. I hope you feel better soon! Trista

FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placeboTo: MEDWATCH@...MedWatch - The FDA Safety Information and Adverse Event Reporting ProgramGlaxoKline (GSK) and FDA notified healthcare professionals ofchanges to the Clinical Worsening and Suicide Risk subsection of theWARNINGS section in the prescribing Information for Paxil and Paxil CR.These labeling changes relate to adult patients, particularly those whoare younger adults. A recent meta-analysis conducted of suicidal behavior and ideation inplacebo-controlled clinical trials of paroxetine in adult patients withpsychiatric disorders including Major Depressive Disorder (MDD), otherdepression and non-depression disorders. Results of this analysis showeda higher frequency of suicidal behavior in young adults treated withparoxetine compared with placebo. Further, in the analysis of adultswith MDD (all ages), the frequency of suicidal behavior was higher inpatients treated with paroxetine compared with placebo. This differencewas statistically significant; however, as the absolute number andincidence of events are small, these data should be interpreted withcaution. All of the reported events of suicidal behavior in the adultpatients with MDD were non-fatal suicide attempts, and the majority ofthese attempts (8 of 11) were in younger adults aged 18-30. These MDDdata suggest that the higher frequency observed in the younger adultpopulation across psychiatric disorders may extend beyond the age of 24.It is important that all patients, especially young adults and those whoare improving, receive careful monitoring during paroxetine therapyregardless of the condition being treated. Read the complete MedWatch 2006 Safety Summary, including links to theDear Healthcare Professional Letter and the revised approved productlabeling at: http://www.fda.gov/medwatch/safety/2006/safety06.htm#paxil_________________________________________________________________Thank you for using FDA MedWatch as a trusted source for timely safety information on drugs, devices and diagnostics regulated by the U.S. Food and Drug Administration. If you find this e-mail notification helpful, please consider telling colleagues and friends about MedWatch and this e-mail notification process. They can learn more and subscribe to the e-list at http://www.fda.gov/medwatch.To send a comment or question to the MedWatch program: http://www.fda.gov/medwatch/feedback.htm

[Guest guest]

$170 would be too much for me too so don't feel bad!!

Peace and Blessings

~*~ Akiba ~*~

Pragmatic Visionary

http://yodamamma.blogspot.com/

http://www.solay-twinflames.com

-- Re: Fwd: FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placebo

Valene, I have a cousin who was prescribed this junk, and became very

suicidal. He told his doctor and they

switched him to something MUCH milder,

and he took it for a few months, and has been off it for years. Question your doctor, as this stuff, as Sharon

pointed out in her citation, has a bad

reputation. Love to you, Valene! n

FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placeboTo: MEDWATCH@...MedWatch - The FDA Safety Information and Adverse Event Reporting ProgramGlaxoKline (GSK) and FDA notified healthcare professionals ofchanges to the Clinical Worsening and Suicide Risk subsection of theWARNINGS section in the prescribing Information for Paxil and Paxil CR.These labeling changes relate to adult patients, particularly those whoare younger adults. A recent meta-analysis conducted of suicidal behavior and ideation inplacebo-controlled clinical trials of paroxetine in adult patients withpsychiatric disorders including Major Depressive Disorder (MDD), otherdepression and non-depression disorders. Results of this analysis showeda higher frequency of suicidal behavior in young adults treated withparoxetine compared with placebo. Further, in the analysis of adultswith MDD (all ages), the frequency of suicidal behavior was higher inpatients treated with paroxetine compared with placebo. This differencewas statistically significant; however, as the absolute number andincidence of events are small, these data should be interpreted withcaution. All of the reported events of suicidal behavior in the adultpatients with MDD were non-fatal suicide attempts, and the majority ofthese attempts (8 of 11) were in younger adults aged 18-30. These MDDdata suggest that the higher frequency observed in the younger adultpopulation across psychiatric disorders may extend beyond the age of 24.It is important that all patients, especially young adults and those whoare improving, receive careful monitoring during paroxetine therapyregardless of the condition being treated. Read the complete MedWatch 2006 Safety Summary, including links to theDear Healthcare Professional Letter and the revised approved productlabeling at: http://www.fda.gov/medwatch/safety/2006/safety06.htm#paxil_________________________________________________________________Thank you for using FDA MedWatch as a trusted source for timely safety information on drugs, devices and diagnostics regulated by the U.S. Food and Drug Administration. If you find this e-mail notification helpful, please consider telling colleagues and friends about MedWatch and this e-mail notification process. They can learn more and subscribe to the e-list at http://www.fda.gov/medwatch.To send a comment or question to the MedWatch program: http://www.fda.gov/medwatch/feedback.htm

[Guest guest]

It sounds like a lot, Val. Are there any of the med programs you can qualify for? Or maybe something through your county (here we have RBHA -- regional Behavioral Health... something like that lol, and each county has their own)? I wish it weren't so hard to get the meds when we feel we need them. Hugs, Challis Valene wrote: Challis- For both meds together, the cost is $170.00 per month. I know it doesn't sound like much, but right now...$20.00 is too much. Val -- Re: Fwd: FDA MedWatch - Paxil/Paxil CR

(paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placebo Valene, I have a cousin who was prescribed this junk, and became very suicidal. He told his doctor and they switched him to something MUCH milder, and he took it for a few months, and has been off it for years. Question your doctor, as this stuff, as Sharon pointed out in her citation, has a bad reputation. Love to you, Valene! n FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent

meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placeboTo: MEDWATCH@...MedWatch - The FDA Safety Information and Adverse Event Reporting ProgramGlaxoKline (GSK) and FDA notified healthcare professionals ofchanges to the Clinical Worsening and Suicide Risk subsection of theWARNINGS section in the prescribing Information for Paxil and Paxil CR.These labeling changes relate to adult patients, particularly those whoare younger adults. A recent meta-analysis conducted of suicidal behavior and ideation inplacebo-controlled clinical trials of paroxetine in adult patients withpsychiatric disorders including Major Depressive Disorder (MDD), otherdepression and non-depression disorders. Results of this analysis showeda higher frequency of suicidal behavior in young adults treated withparoxetine compared with placebo. Further,

in the analysis of adultswith MDD (all ages), the frequency of suicidal behavior was higher inpatients treated with paroxetine compared with placebo. This differencewas statistically significant; however, as the absolute number andincidence of events are small, these data should be interpreted withcaution. All of the reported events of suicidal behavior in the adultpatients with MDD were non-fatal suicide attempts, and the majority ofthese attempts (8 of 11) were in younger adults aged 18-30. These MDDdata suggest that the higher frequency observed in the younger adultpopulation across psychiatric disorders may extend beyond the age of 24.It is important that all patients, especially young adults and those whoare improving, receive careful monitoring during paroxetine therapyregardless of the condition being treated. Read the complete MedWatch 2006 Safety Summary, including links to theDear Healthcare

Professional Letter and the revised approved productlabeling at: http://www.fda.gov/medwatch/safety/2006/safety06.htm#paxil_________________________________________________________________Thank you for using FDA MedWatch as a trusted source for timely safety information on drugs, devices and diagnostics regulated by the U.S. Food and Drug Administration. If you find this e-mail notification helpful, please consider telling colleagues and friends about MedWatch and this e-mail notification process. They can learn more and subscribe to the e-list at http://www.fda.gov/medwatch.To send a comment or question to the MedWatch program: http://www.fda.gov/medwatch/feedback.htm

[Guest guest]

Challis-

I'm not sure where to go from here. I used to get them from the Mental Health Clinic here. They go by your income. I had none, so mine were free. Well, then it changed. They told me that in order to continue to get them, I had to bring in proof that I had been denied disability. Sooo much was going on back then, that I just stopped taking it. I had been denied disability, but I had misplaced the letter. When I asked them to send me another letter or send it to the Mental Health Clinic, they refused. I don't remember the excuse they gave me, but it was so obviously bogus, it was almost laughable! Something, about not being allowed to send out copies, or some such nonsense.

Really, you'd have to live in NC to know what I'm talking about. This is such a backwards state. I could get into that and ramble all day! But, it would serve no purpose. Vice it to say ...If you are walking and can hold a conversation, then you must be able bodied. Doesn't matter if you have limitations.

God bless...Val

-- Re: Fwd: FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placebo

Valene, I have a cousin who was prescribed this junk, and became very

suicidal. He told his doctor and they

switched him to something MUCH milder,

and he took it for a few months, and has been off it for years. Question your doctor, as this stuff, as Sharon

pointed out in her citation, has a bad

reputation. Love to you, Valene! n

FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placeboTo: MEDWATCH@...MedWatch - The FDA Safety Information and Adverse Event Reporting ProgramGlaxoKline (GSK) and FDA notified healthcare professionals ofchanges to the Clinical Worsening and Suicide Risk subsection of theWARNINGS section in the prescribing Information for Paxil and Paxil CR.These labeling changes relate to adult patients, particularly those whoare younger adults. A recent meta-analysis conducted of suicidal behavior and ideation inplacebo-controlled clinical trials of paroxetine in adult patients withpsychiatric disorders including Major Depressive Disorder (MDD), otherdepression and non-depression disorders. Results of this analysis showeda higher frequency of suicidal behavior in young adults treated withparoxetine compared with placebo. Further, in the analysis of adultswith MDD (all ages), the frequency of suicidal behavior was higher inpatients treated with paroxetine compared with placebo. This differencewas statistically significant; however, as the absolute number andincidence of events are small, these data should be interpreted withcaution. All of the reported events of suicidal behavior in the adultpatients with MDD were non-fatal suicide attempts, and the majority ofthese attempts (8 of 11) were in younger adults aged 18-30. These MDDdata suggest that the higher frequency observed in the younger adultpopulation across psychiatric disorders may extend beyond the age of 24.It is important that all patients, especially young adults and those whoare improving, receive careful monitoring during paroxetine therapyregardless of the condition being treated. Read the complete MedWatch 2006 Safety Summary, including links to theDear Healthcare Professional Letter and the revised approved productlabeling at: http://www.fda.gov/medwatch/safety/2006/safety06.htm#paxil_________________________________________________________________Thank you for using FDA MedWatch as a trusted source for timely safety information on drugs, devices and diagnostics regulated by the U.S. Food and Drug Administration. If you find this e-mail notification helpful, please consider telling colleagues and friends about MedWatch and this e-mail notification process. They can learn more and subscribe to the e-list at http://www.fda.gov/medwatch.To send a comment or question to the MedWatch program: http://www.fda.gov/medwatch/feedback.htm

[Guest guest]

I am weaning this time. The first time I just didn't have the money to fill all rx's, so I left that one to fill with next paycheck. At least five or six days without before I became ill. We were at our breaders house picking up a new baby bird. It hit me like a ton of bricks. To make a long story short I fainted and ended up in the ER. I was the one to figure it out not the doc's. That's when I did some research and read others opinions. I weaned and weaned...and would end up putting a pill in my mouth. This time I was better prepared mentally and spiritually. I know I've got it this time...still feel a little poopy on and off, but I am doing it. Dawn KValene wrote: I'm listening, Dawn- I'm sorry you are having such a tough time on this stuff! Are you weaning yourself off of it, or are you trying the "cold turkey" approach? I have heard that with all anti-depressants, you should be weaned off of them because of the symptoms. I do hope you start feeling better soon. And really, I am listening. I'm doing my homework. I won't be taking the Paxil until I find out if it is the best for me. Blessed be...Val -- Re: Fwd: FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placebo Valene, I have a cousin who was prescribed this junk, and became very suicidal. He told his doctor and they switched him to something MUCH milder, and he took it for a few months, and has been off it for years. Question your doctor, as this stuff, as Sharon pointed out in her citation, has a bad reputation. Love to you, Valene!

n FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placeboTo: MEDWATCH@...MedWatch - The FDA Safety Information and Adverse Event Reporting ProgramGlaxoKline (GSK) and FDA notified healthcare professionals ofchanges to the Clinical Worsening and Suicide Risk subsection of theWARNINGS section in the prescribing Information for Paxil and Paxil CR.These labeling changes relate to adult patients, particularly those whoare younger adults. A recent meta-analysis conducted of suicidal behavior and ideation inplacebo-controlled clinical trials of paroxetine in adult patients withpsychiatric disorders including Major Depressive Disorder (MDD), otherdepression and non-depression disorders. Results

of this analysis showeda higher frequency of suicidal behavior in young adults treated withparoxetine compared with placebo. Further, in the analysis of adultswith MDD (all ages), the frequency of suicidal behavior was higher inpatients treated with paroxetine compared with placebo. This differencewas statistically significant; however, as the absolute number andincidence of events are small, these data should be interpreted withcaution. All of the reported events of suicidal behavior in the adultpatients with MDD were non-fatal suicide attempts, and the majority ofthese attempts (8 of 11) were in younger adults aged 18-30. These MDDdata suggest that the higher frequency observed in the younger adultpopulation across psychiatric disorders may extend beyond the age of 24.It is important that all patients, especially young adults and those whoare improving, receive careful monitoring during paroxetine

therapyregardless of the condition being treated. Read the complete MedWatch 2006 Safety Summary, including links to theDear Healthcare Professional Letter and the revised approved productlabeling at: http://www.fda.gov/medwatch/safety/2006/safety06.htm#paxil_________________________________________________________________Thank you for using FDA MedWatch as a trusted source for timely safety information on drugs, devices and diagnostics regulated by the U.S. Food and Drug Administration. If you find this e-mail notification helpful, please consider telling colleagues and friends about MedWatch and this e-mail notification process. They can learn more and subscribe to the e-list at http://www.fda.gov/medwatch.To send a comment or question to the MedWatch program: http://www.fda.gov/medwatch/feedback.htm

[Guest guest]

Evil...that is the best way to describe it! Dawn KTrista wrote: Dawn, It took me 3 months to start feeling better after going off it. It is truly an evil drug. I hope you feel better soon! Trista FDA MedWatch - Paxil/Paxil CR (paroxetine HCl) and recent meta-analysis of paroxetine showed a higher frequency of suicidal behavior in young adults treated with paroxetine compared with placeboTo: MEDWATCH@...MedWatch - The FDA Safety Information and Adverse

Event Reporting ProgramGlaxoKline (GSK) and FDA notified healthcare professionals ofchanges to the Clinical Worsening and Suicide Risk subsection of theWARNINGS section in the prescribing Information for Paxil and Paxil CR.These labeling changes relate to adult patients, particularly those whoare younger adults. A recent meta-analysis conducted of suicidal behavior and ideation inplacebo-controlled clinical trials of paroxetine in adult patients withpsychiatric disorders including Major Depressive Disorder (MDD), otherdepression and non-depression disorders. Results of this analysis showeda higher frequency of suicidal behavior in young adults treated withparoxetine compared with placebo. Further, in the analysis of adultswith MDD (all ages), the frequency of suicidal behavior was higher inpatients treated with paroxetine compared with placebo. This differencewas statistically significant; however, as the

absolute number andincidence of events are small, these data should be interpreted withcaution. All of the reported events of suicidal behavior in the adultpatients with MDD were non-fatal suicide attempts, and the majority ofthese attempts (8 of 11) were in younger adults aged 18-30. These MDDdata suggest that the higher frequency observed in the younger adultpopulation across psychiatric disorders may extend beyond the age of 24.It is important that all patients, especially young adults and those whoare improving, receive careful monitoring during paroxetine therapyregardless of the condition being treated. Read the complete MedWatch 2006 Safety Summary, including links to theDear Healthcare Professional Letter and the revised approved productlabeling at: http://www.fda.gov/medwatch/safety/2006/safety06.htm#paxil_________________________________________________________________Thank

you for using FDA MedWatch as a trusted source for timely safety information on drugs, devices and diagnostics regulated by the U.S. Food and Drug Administration. If you find this e-mail notification helpful, please consider telling colleagues and friends about MedWatch and this e-mail notification process. They can learn more and subscribe to the e-list at http://www.fda.gov/medwatch.To send a comment or question to the MedWatch program: http://www.fda.gov/medwatch/feedback.htm